|Mr. Geoff MacKay||Co- Founder, Pres, CEO & Director||811.23k||N/A||1966|
|Mr. Erik Ostrowski M.B.A.||CFO & Treasurer||597.08k||N/A||1973|
|Mr. Steven N. Avruch J.D.||Chief Legal Officer & Sec.||506.68k||N/A||1961|
|Mr. Jeffrey Medin Ph.D.||Scientific Founder||N/A||N/A||N/A|
|Mr. Matthew Arnold||Head of Operations||N/A||N/A||N/A|
|Mr. Kim Raineri M.B.A.||Chief Manufacturing & Technology Officer||N/A||N/A||N/A|
|Dr. Christopher Mason FMEDSCI, M.D., Ph.D., FRCS||Chief Scientific Officer||N/A||N/A||1958|
|Ms. Monique Da Silva||Sr. VP of Corp. Communications||N/A||N/A||N/A|
|Ms. Georgette Verdin||Chief HR Officer||N/A||N/A||N/A|
|Ms. Deanna M. Petersen MBA||Chief Bus. Officer||N/A||N/A||1962|
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 8.